抗体治療薬の世界市場

抗体治療薬の世界市場は2030年までに34億米ドルに達する見込み

2024年に17億米ドルと推定される抗体治療薬の世界市場は、2024年から2030年にかけてCAGR 12.8%で成長し、2030年には34億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるモノクローナル抗体治療薬は、CAGR 10.9％を記録し、分析期間終了までに13億米ドルに達すると予測されています。ポリクローナル抗体治療薬分野の成長率は、分析期間中CAGR16.0％と推定されます。

米国市場は4億5,270万米ドルと推定、中国はCAGR 16.9％で成長すると予測

米国の抗体治療薬市場は、2024年に4億5,270万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを16.9%として、2030年までに7億1,260万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.6%と11.3%と予測されています。欧州では、ドイツがCAGR 10.1%で成長すると予測されています。

世界の抗体治療薬市場- 主要動向と促進要因のまとめ

なぜ抗体治療薬は幅広い疾患の治療パラダイムを変革するのか？

抗体治療薬は、オフターゲット効果を低減し、高度に標的化された、メカニズム特異的な治療を提供する能力により、現代のバイオ医薬品開発の礎石として登場しました。モノクローナル抗体（mAbs）は、疾患細胞や病原体上の特異的抗原を認識して結合するように設計されており、免疫応答の調節、疾患ドライバーの中和、細胞傷害メカニズムの誘発において高い精度を発揮します。その汎用性の高さは、がんや自己免疫疾患から感染症や慢性炎症性疾患に至るまで、増大する様々な疾患での成功を支えています。

腫瘍学においては、腫瘍特異的抗原を直接標的とする薬剤や、T細胞応答を再活性化するチェックポイント阻害剤によって、抗体治療薬は治療に革命をもたらしました。モノクローナル抗体と化学療法や他の免疫療法との併用は、非ホジキンリンパ腫、乳がん、非小細胞肺がんなどにおいて、有意な生存利益を示しています。自己免疫疾患や炎症性疾患では、異常な免疫活性化を引き起こすサイトカインや細胞表面タンパク質を阻害するために抗体が広く使用されており、従来の免疫抑制剤と比較して高い忍容性で疾患をコントロールすることが可能です。

治療効果だけでなく、抗体はモジュール性と機能的適応性を備えています。二重特異性抗体、抗体薬物複合体（ADC）、Fc修飾抗体などの抗体工学の進歩は、新たな作用機序、組織ターゲティング、ペイロードデリバリー戦略を可能にしています。生物学的な理解が深まり、疾患経路がより詳細にマッピングされるにつれて、情勢は、急性疾患と慢性疾患の両方の領域において、より個別化された、より有効性の高い介入を提供する立場にあります。

技術的進歩と製造革新はどのように治療価値を高めているのか？

抗体の発見と開発は、ハイスループットスクリーニング、次世代シークエンシング、ファージや酵母ディスプレイ技術の飛躍的進歩によって加速されており、高親和性抗原特異的候補の迅速な同定が可能になっています。ヒト化技術や完全ヒト抗体ライブラリーは、免疫原性プロファイルを向上させ、有害免疫反応のリスクを低減し、臨床応用の可能性を広げています。これらの技術革新は開発期間を短縮し、初期段階のパイプラインにおける成功率を向上させています。

製造面では、プロセスの最適化とプラットフォームベースの生産システムにより、コスト効率、スケーラビリティ、規制遵守が向上しています。CHO（チャイニーズハムスター卵巣）細胞を上流生産に使用し、連続バイオプロセスやシングルユースシステムと組み合わせることで、モノクローナル抗体の生産が効率化されています。高度なクロマトグラフィーやリアルタイム品質モニタリングなどの下流の精製技術は、バッチの一貫性を高め、コンタミネーションのリスクを低減し、ますます厳しくなる世界の規制の期待に応えています。

さらに、製剤科学の進歩により、患者の利便性とコンプライアンスを向上させる皮下および筋肉内投与ルートが可能になりつつあります。長時間作用型製剤、自動注射器、体内注入システムは、在宅投与を容易にし、ヘルスケア資源の負担を軽減するために開発されています。このような薬物送達の革新は、従来の静脈内投与ではアクセスが制限され、治療費を押し上げる可能性のある慢性期医療や腫瘍学において特に重要です。抗体治療薬が標準治療のプロトコールに組み込まれるようになるにつれ、使いやすい製剤は、治療薬の採用と患者の転帰を最大化するために不可欠となります。

抗体ベースの市場拡大を促進している適応症と地域は？

トラスツズマブ、リツキシマブ、ペムブロリズマブなどの代表的な薬剤の高いアンメットニーズ、確かな臨床効果、商業的成功が後押ししています。免疫療法併用レジメンの台頭とバイオマーカー主導の治療選択により、がん治療における中心的薬剤としての抗体の役割が強化されつつあります。関節リウマチ、乾癬、炎症性腸疾患などの自己免疫疾患も主要な治療領域であり、抗TNF抗体、抗IL-6抗体、抗インテグリン抗体が引き続き治療レジメンの中心となっています。

神経変性疾患、感染症、希少遺伝性疾患における新たな適応症は、抗体市場の範囲を拡大しつつあります。アルツハイマー病のアミロイドベータやタウを標的とする抗体候補が後期臨床試験を進行中であり、HIV、COVID-19、呼吸器合胞体ウイルス（RSV）に対する広範な中和抗体の開発が進められています。希少疾病領域では、アンメットニーズの高い少人数疾患に対応するためにアンメットニーズが活用され、規制当局の優遇措置やファストトラック指定を受けています。

地域的には、北米と欧州が、革新的な治療法への早期アクセス、成熟した薬事規制、強力なヘルスケアインフラにより、現在の市場収益を独占しています。しかし、アジア太平洋地域は、医療費の増加、生物製剤の製造能力の拡大、中国、日本、韓国などの国々における支持的な政策枠組みに後押しされ、急成長を遂げています。新興市場が生物学的製剤の技術革新と治療法の自給自足に多額の投資を行っているため、地域ごとの研究開発努力、バイオシミラーの浸透、臨床試験の拡大が地域のダイナミクスをさらに強めています。

規制の変化、バイオシミラー競合、個別化医療は市場情勢をどのように形成しているか？

進化する規制の枠組みは、厳格な安全性と有効性のベンチマークを維持しながら、抗体医薬品の承認を加速し、技術革新を支援しています。米国FDAや欧州医薬品庁（EMA）は、画期的治療薬指定（Breakthrough Therapy Designation）、迅速承認（Accelerated Approval）、プライム（PRIME）ステータスなどの迅速審査パスウェイを導入し、重要疾患領域における有望な抗体医薬へのアクセスを促進しています。地域間の規制調和への取り組みも、多国間の臨床試験実施と市場参入の同期化を後押ししています。

成熟市場では、第一世代のブロックバスター抗体の特許が切れるにつれて、バイオシミラーの競合が増加しています。バイオシミラー医薬品の普及は、価格政策、医師の受容性、償還の仕組みなどにより地域によって異なるが、欧州やアジアの一部ではコスト構造や市場アクセスが再構築されつつあります。イノベーター企業は、次世代製剤、合剤、従来の静脈内投与の皮下注製剤などのライフサイクルマネジメント戦略を通じて対応しています。これと並行して、オリジネーターはバイオシミラーの侵食に直面しても価値を維持できるよう、パイプラインの多様化に投資しています。

個別化医療の動向は、バイオマーカーを指標とした抗体治療へのシフトを促し、コンパニオン診断薬は治療に反応する可能性の高い患者集団を特定するために不可欠となっています。このような精密なアプローチは、特に腫瘍学と免疫学において、治療効果と支払者の受容性を向上させています。ゲノムプロファイリングとAI主導の創薬が成熟するにつれ、標的治療経路への抗体の統合は深まり、生物製剤、診断薬、データ活用による治療計画の境界線が曖昧になると予想されます。

抗体治療薬市場の成長を促進する要因は何か？

抗体治療薬市場は、複雑な慢性疾患や免疫疾患の有病率の増加、精密治療に対する需要の高まり、疾患修飾における生物学的製剤の継続的な成功により、堅調なペースで拡大しています。主な促進要因としては、抗体工学における持続的な技術革新、治療用途の多様化、高価値治療への地理的アクセスの拡大などが挙げられます。また、二重特異性抗体、抗体薬物複合体、ナノ抗体など、後期開発段階にある新規抗体フォーマットの強力なパイプラインも市場の追い風となっています。

戦略的提携、ライセンス契約、競合情勢を形成しているのはM&Aであり、大手製薬企業やバイオテクノロジー企業は提携を活用して創薬、製造、世界市場への参入を加速させています。一方、世界な製造インフラ、臨床試験ネットワーク、規制の調和への投資は、市場投入までの時間を短縮し、先進国・新興経済諸国を問わずアクセスを拡大しています。候補化合物のスクリーニングと臨床試験の最適化におけるデジタルツールの役割の拡大は、イノベーションの効率と開発の成功率をさらに押し上げています。

今後、抗体治療薬市場がどのような軌道をたどるかは、コストに敏感でアウトカム重視の傾向が強まるヘルスケアエコシステムにおいて、利害関係者が価格圧力、バイオシミラー競争、患者アクセスにいかに効果的に対処するかにかかっています。生物製剤がデジタルヘルス、個別化診断、再生プラットフォームと融合し続ける中、抗体治療薬が次世代標的医療の統一軸となる可能性はあるのだろうか。

セグメント

フォーマット（モノクローナル抗体、ポリクローナル抗体療法、二重特異性抗体、抗体フラグメントおよびその他のフォーマット）、疾患領域（自己免疫疾患および炎症性疾患、神経学、骨学、血液学、腫瘍学、感染症、免疫学、その他の疾患領域）、供給源（ヒト、ヒト化、キメラ）、投与経路（静脈内、皮下、その他の投与経路）、エンドユース（病院、長期療養施設、その他のエンドユース）

調査対象企業の例（合計 34注目）

• AbbVie Inc.
• AbCellera Biologics Inc.
• Amgen Inc.
• Argenx SE
• AstraZeneca plc
• Bayer AG
• BeiGene, Ltd.
• Biogen Inc.
• BioNTech SE
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• Genmab A/S
• GlaxoSmithKline plc
• Johnson & Johnson
• MacroGenics, Inc.
• Merck & Co., Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Antibody Therapeutics Market to Reach US$3.4 Billion by 2030

The global market for Antibody Therapeutics estimated at US$1.7 Billion in the year 2024, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. Monoclonal Antibody Therapeutics, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Polyclonal Antibody Therapeutics segment is estimated at 16.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$452.7 Million While China is Forecast to Grow at 16.9% CAGR

The Antibody Therapeutics market in the U.S. is estimated at US$452.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$712.6 Million by the year 2030 trailing a CAGR of 16.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 11.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Antibody Therapeutics Market - Key Trends & Drivers Summarized

Why Are Antibody Therapeutics Transforming the Treatment Paradigm Across a Broad Range of Diseases?

Antibody therapeutics have emerged as a cornerstone of modern biopharmaceutical development due to their ability to offer highly targeted, mechanism-specific treatment with reduced off-target effects. Engineered to recognize and bind to specific antigens on diseased cells or pathogens, monoclonal antibodies (mAbs) deliver high precision in modulating immune responses, neutralizing disease drivers, or triggering cytotoxic mechanisms. Their versatility underpins their success across a growing spectrum of diseases, from cancer and autoimmune disorders to infectious diseases and chronic inflammatory conditions.

In oncology, antibody therapeutics have revolutionized treatment with agents that directly target tumor-specific antigens or checkpoint inhibitors that reactivate T-cell responses. Combinations of monoclonal antibodies with chemotherapeutics or other immunotherapies have shown significant survival benefits in cancers such as non-Hodgkin’s lymphoma, breast cancer, and non-small cell lung cancer. In autoimmune and inflammatory disorders, antibodies are widely used to inhibit cytokines or cell surface proteins responsible for aberrant immune activation, enabling disease control with higher tolerability compared to conventional immunosuppressants.

Beyond therapeutic efficacy, antibodies offer modularity and functional adaptability. Advances in antibody engineering-including bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-modified variants-are enabling new mechanisms of action, tissue targeting, and payload delivery strategies. As biological understanding deepens and disease pathways become more finely mapped, antibody therapeutics are positioned to deliver increasingly personalized, high-efficacy interventions across both acute and chronic disease landscapes.

How Are Technological Advancements and Manufacturing Innovation Driving Therapeutic Value?

Antibody discovery and development are being accelerated by breakthroughs in high-throughput screening, next-generation sequencing, and phage or yeast display technologies, which enable rapid identification of high-affinity, antigen-specific candidates. Humanization techniques and fully human antibody libraries are enhancing immunogenicity profiles, reducing the risk of adverse immune responses, and expanding clinical applicability. These innovations are shortening development timelines and improving success rates in early-stage pipelines.

On the manufacturing side, process optimization and platform-based production systems are improving cost-efficiency, scalability, and regulatory compliance. The use of CHO (Chinese Hamster Ovary) cells in upstream production, combined with continuous bioprocessing and single-use systems, is streamlining monoclonal antibody output. Downstream purification technologies-such as advanced chromatography and real-time quality monitoring-are enhancing batch consistency and reducing contamination risks, meeting increasingly stringent global regulatory expectations.

Moreover, advances in formulation science are enabling subcutaneous and intramuscular delivery routes that improve patient convenience and compliance. Long-acting formulations, auto-injector devices, and on-body infusion systems are being developed to facilitate home administration and reduce healthcare resource burdens. These delivery innovations are particularly important in chronic care and oncology, where traditional IV administration can limit access and drive up treatment costs. As therapeutic antibodies become more integrated into standard-of-care protocols, user-friendly formulations are essential to maximizing therapeutic adoption and patient outcomes.

Which Indications and Geographies Are Fueling Market Expansion for Antibody-Based Therapies?

Oncology remains the largest and most mature application area for antibody therapeutics, driven by high unmet need, robust clinical efficacy, and strong commercial success of leading drugs such as trastuzumab, rituximab, and pembrolizumab. The rise of combination immunotherapy regimens and biomarker-driven treatment selection is reinforcing the role of antibodies as central agents in cancer care. Autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease also represent major therapeutic areas, where anti-TNF, anti-IL-6, and anti-integrin antibodies continue to anchor treatment regimens.

Emerging indications in neurodegenerative disease, infectious disease, and rare genetic disorders are expanding the antibody market’s scope. Antibody candidates targeting amyloid-beta and tau in Alzheimer’s disease are progressing through late-stage trials, while broadly neutralizing antibodies are being developed for HIV, COVID-19, and respiratory syncytial virus (RSV). In the orphan disease space, antibody therapeutics are being leveraged to address small-patient-population diseases with high unmet need, attracting regulatory incentives and fast-track designations.

Geographically, North America and Europe dominate current market revenue due to early access to innovative therapies, mature regulatory pathways, and strong healthcare infrastructure. However, Asia-Pacific is witnessing the fastest growth, fueled by rising healthcare expenditure, expanding biologics manufacturing capabilities, and supportive policy frameworks in countries such as China, Japan, and South Korea. Localized R&D efforts, biosimilar penetration, and clinical trial expansion are further strengthening regional dynamics, as emerging markets invest heavily in biologic innovation and therapeutic self-sufficiency.

How Are Regulatory Shifts, Biosimilar Competition, and Personalized Medicine Shaping the Market Landscape?

Evolving regulatory frameworks are accelerating antibody drug approvals and supporting innovation while maintaining rigorous safety and efficacy benchmarks. Agencies such as the U.S. FDA and EMA have introduced expedited review pathways-including Breakthrough Therapy Designation, Accelerated Approval, and PRIME status-to facilitate access to promising antibody-based treatments in critical disease areas. Regulatory harmonization efforts across regions are also aiding multinational trial execution and synchronized market entry.

Biosimilar competition is increasing in mature markets as patents on first-generation blockbuster antibodies expire. While biosimilar uptake varies by geography due to pricing policy, physician acceptance, and reimbursement mechanisms, it is reshaping cost structures and market access in Europe and parts of Asia. Innovator companies are responding through lifecycle management strategies, including next-generation formulations, fixed-dose combinations, and subcutaneous versions of legacy IV therapies. In parallel, originators are investing in pipeline diversification to sustain value in the face of biosimilar erosion.

Personalized medicine trends are driving a shift toward biomarker-guided antibody therapies, with companion diagnostics becoming critical to identifying patient subpopulations likely to respond to treatment. This precision approach is improving therapeutic efficacy and payer acceptance, especially in oncology and immunology. As genomic profiling and AI-driven drug discovery mature, the integration of antibodies into targeted treatment pathways is expected to deepen-blurring the lines between biologics, diagnostics, and data-enabled therapeutic planning.

What Are the Factors Driving Growth in the Antibody Therapeutics Market?

The antibody therapeutics market is expanding at a robust pace, driven by the increasing prevalence of complex chronic and immunological diseases, rising demand for precision treatments, and continued success of biologics in achieving disease modification. Key drivers include sustained innovation in antibody engineering, the diversification of therapeutic applications, and broadening geographic access to high-value therapies. The market is also benefiting from a strong pipeline of novel formats such as bispecifics, antibody-drug conjugates, and nanobodies entering late-stage development.

Strategic alliances, licensing deals, and M&A activity continue to shape the competitive landscape, with big pharma and biotech firms leveraging partnerships to accelerate discovery, manufacturing, and global market entry. Meanwhile, investments in global manufacturing infrastructure, clinical trial networks, and regulatory harmonization are reducing time-to-market and expanding access across developed and emerging economies. The expanding role of digital tools in candidate screening and trial optimization is further boosting innovation efficiency and development success rates.

Looking ahead, the trajectory of the antibody therapeutics market will hinge on how effectively stakeholders address pricing pressure, biosimilar competition, and patient access in an increasingly cost-sensitive and outcomes-focused healthcare ecosystem. As biologics continue to converge with digital health, personalized diagnostics, and regenerative platforms, could antibody therapeutics become the unifying axis of next-generation targeted medicine?

SCOPE OF STUDY:

The report analyzes the Antibody Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Format (Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody Fragment & Other Formats); Disease Area (Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, Other Disease Areas); Source (Human, Humanized, Chimeric); Administration Route (Intravenous, Subcutaneous, Other Administration Routes); End-Use (Hospitals, Long-term Care Facilities, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• AbCellera Biologics Inc.
• Amgen Inc.
• Argenx SE
• AstraZeneca plc
• Bayer AG
• BeiGene, Ltd.
• Biogen Inc.
• BioNTech SE
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Genentech, Inc.
• Genmab A/S
• GlaxoSmithKline plc
• Johnson & Johnson
• MacroGenics, Inc.
• Merck & Co., Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Antibody Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Cancer and Autoimmune Diseases Throws the Spotlight on Antibody-Based Drug Development
  • Expansion of Monoclonal Antibody Pipelines Spurs Growth in Targeted Immunotherapy and Biologics
  • Breakthroughs in Bispecific and Multispecific Antibody Formats Strengthen the Business Case for Complex Therapies
  • Increased Focus on Personalized Medicine Bodes Well for Antibody Drug Conjugate Innovation
  • Growth of mRNA and Vector-Based Platforms Fuels Discovery of Novel Antibody Targets
  • Rising Demand for Subcutaneous and Self-Injectable Formats Drives Patient-Centric Product Development
  • Use of AI and Machine Learning in Antibody Design Optimizes Affinity and Off-Target Minimization
  • Global Investment in Biomanufacturing Infrastructure Supports Scalable Production of Next-Gen Antibodies
  • Regulatory Fast Tracks and Orphan Drug Designations Boost Market Entry for Rare Disease Antibodies
  • Expanded Use in Infectious Disease and Vaccine Applications Broadens Therapeutic Horizons
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antibody Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antibody Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Antibody Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Monoclonal Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Polyclonal Antibody Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Polyclonal Antibody Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Polyclonal Antibody Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Bispecific Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Bispecific Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Bispecific Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antibody Fragment & Other Formats by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antibody Fragment & Other Formats by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Antibody Fragment & Other Formats by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Disease Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Disease Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Autoimmune & Inflammatory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Autoimmune & Inflammatory Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Autoimmune & Inflammatory Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Osteology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Osteology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Osteology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Humanized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Humanized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Humanized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Chimeric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Chimeric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Chimeric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Long-term Care Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Long-term Care Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: World 15-Year Perspective for Long-term Care Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 65: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 66: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 68: USA Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 74: USA Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: USA 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 77: USA Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: USA Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: USA 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 80: USA Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: USA Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: USA 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 89: Canada Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Canada Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Canada 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 92: Canada Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Canada Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Canada 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 95: Canada Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Canada Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Canada 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Japan 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 101: Japan Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Japan Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Japan 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 104: Japan Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Japan Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Japan 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 107: Japan Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Japan Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Japan 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 110: Japan Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Japan Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Japan 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 113: China Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: China Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: China 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 116: China Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: China Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: China 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 119: China Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: China Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: China 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 122: China Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: China Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: China 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 125: China Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: China Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: China 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 128: Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 129: Europe Historic Review for Antibody Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Europe 15-Year Perspective for Antibody Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 131: Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Europe Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Europe 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 134: Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Europe Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Europe 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 137: Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Europe Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Europe 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 140: Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Europe Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Europe 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 143: Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Europe Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Europe 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 146: France Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: France Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: France 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 149: France Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: France Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: France 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 152: France Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: France Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: France 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 155: France Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: France Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: France 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 158: France Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: France Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: France 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 161: Germany Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Germany Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Germany 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 164: Germany Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Germany Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Germany 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 167: Germany Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Germany Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Germany 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 170: Germany Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Germany Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Germany 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 173: Germany Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Germany Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Germany 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 176: Italy Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Italy Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Italy 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 179: Italy Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Italy Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Italy 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 182: Italy Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Italy Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Italy 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 185: Italy Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Italy Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Italy 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 188: Italy Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Italy Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Italy 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 191: UK Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: UK Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: UK 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 194: UK Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UK Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: UK 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 197: UK Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UK Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: UK 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 200: UK Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UK Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: UK 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 203: UK Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UK Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: UK 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 206: Spain Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Spain Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Spain 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 209: Spain Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Spain Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Spain 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 212: Spain Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Spain Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Spain 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 215: Spain Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Spain Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Spain 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 218: Spain Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Spain Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Spain 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 221: Russia Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Russia Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Russia 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 224: Russia Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Russia Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Russia 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 227: Russia Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Russia Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Russia 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 230: Russia Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Russia Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Russia 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 233: Russia Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Russia Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Russia 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Europe Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Europe 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Europe Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Europe 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Europe Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Europe 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Europe Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Europe 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Europe Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Europe Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Europe 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 252: Asia-Pacific Historic Review for Antibody Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Asia-Pacific Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Asia-Pacific Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 260: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Asia-Pacific Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 263: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Asia-Pacific Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 266: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Asia-Pacific Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Asia-Pacific 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 269: Australia Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Australia Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Australia 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 272: Australia Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Australia Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Australia 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 275: Australia Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Australia Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Australia 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 278: Australia Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Australia Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Australia 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 281: Australia Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Australia Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Australia 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 284: India Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: India Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: India 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 287: India Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: India Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: India 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 290: India Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: India Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: India 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 293: India Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: India Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: India 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 296: India Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: India Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: India 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 299: South Korea Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: South Korea Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: South Korea 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 302: South Korea Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: South Korea Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: South Korea 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 305: South Korea Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: South Korea Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: South Korea 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 308: South Korea Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: South Korea Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: South Korea 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 311: South Korea Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: South Korea Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: South Korea 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Asia-Pacific Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Asia-Pacific Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Asia-Pacific Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Asia-Pacific Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Asia-Pacific 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Asia-Pacific Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Asia-Pacific 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 329: Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 330: Latin America Historic Review for Antibody Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Latin America 15-Year Perspective for Antibody Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 332: Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Latin America Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Latin America 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 335: Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Latin America Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Latin America 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 338: Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Latin America Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Latin America 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 341: Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Latin America Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Latin America 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 344: Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Latin America Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Latin America 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 347: Argentina Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Argentina Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Argentina 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 350: Argentina Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Argentina Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Argentina 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 353: Argentina Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Argentina Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Argentina 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 356: Argentina Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Argentina Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Argentina 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 359: Argentina Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Argentina Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Argentina 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 362: Brazil Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Brazil Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Brazil 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 365: Brazil Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Brazil Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Brazil 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 368: Brazil Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Brazil Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Brazil 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 371: Brazil Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Brazil Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Brazil 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 374: Brazil Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Brazil Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Brazil 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 377: Mexico Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Mexico Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Mexico 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 380: Mexico Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Mexico Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Mexico 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 383: Mexico Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Mexico Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Mexico 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 386: Mexico Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Mexico Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Mexico 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 389: Mexico Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Mexico Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Mexico 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Latin America Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Latin America 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Latin America Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Latin America 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Latin America Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Latin America 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Latin America Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Latin America 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Latin America Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Latin America Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Latin America 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 407: Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 408: Middle East Historic Review for Antibody Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 409: Middle East 15-Year Perspective for Antibody Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 410: Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Middle East Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 412: Middle East 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 413: Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Middle East Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 415: Middle East 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 416: Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Middle East Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 418: Middle East 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 419: Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Middle East Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 421: Middle East 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 422: Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Middle East Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 424: Middle East 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 425: Iran Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Iran Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 427: Iran 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 428: Iran Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Iran Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 430: Iran 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 431: Iran Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Iran Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 433: Iran 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 434: Iran Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Iran Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 436: Iran 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 437: Iran Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Iran Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 439: Iran 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 440: Israel Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Israel Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 442: Israel 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 443: Israel Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Israel Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 445: Israel 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 446: Israel Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Israel Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 448: Israel 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 449: Israel Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Israel Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 451: Israel 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 452: Israel Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Israel Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 454: Israel 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Saudi Arabia Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 457: Saudi Arabia 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Saudi Arabia Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 460: Saudi Arabia 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 461: Saudi Arabia Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 462: Saudi Arabia Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 463: Saudi Arabia 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 464: Saudi Arabia Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 465: Saudi Arabia Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 466: Saudi Arabia 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 467: Saudi Arabia Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 468: Saudi Arabia Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 469: Saudi Arabia 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 470: UAE Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 471: UAE Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 472: UAE 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 473: UAE Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 474: UAE Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 475: UAE 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 476: UAE Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 477: UAE Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 478: UAE 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 479: UAE Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 480: UAE Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 481: UAE 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 482: UAE Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 483: UAE Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 484: UAE 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 486: Rest of Middle East Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 487: Rest of Middle East 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Rest of Middle East Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 490: Rest of Middle East 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 491: Rest of Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Rest of Middle East Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 493: Rest of Middle East 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 494: Rest of Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Rest of Middle East Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 496: Rest of Middle East 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 497: Rest of Middle East Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 498: Rest of Middle East Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 499: Rest of Middle East 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Antibody Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 500: Africa Recent Past, Current & Future Analysis for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Africa Historic Review for Antibody Therapeutics by Format - Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 502: Africa 15-Year Perspective for Antibody Therapeutics by Format - Percentage Breakdown of Value Sales for Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody and Antibody Fragment & Other Formats for the Years 2015, 2025 & 2030
  • TABLE 503: Africa Recent Past, Current & Future Analysis for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Africa Historic Review for Antibody Therapeutics by Disease Area - Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 505: Africa 15-Year Perspective for Antibody Therapeutics by Disease Area - Percentage Breakdown of Value Sales for Infectious Diseases, Immunology, Other Disease Areas, Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 506: Africa Recent Past, Current & Future Analysis for Antibody Therapeutics by Source - Human, Humanized and Chimeric - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 507: Africa Historic Review for Antibody Therapeutics by Source - Human, Humanized and Chimeric Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 508: Africa 15-Year Perspective for Antibody Therapeutics by Source - Percentage Breakdown of Value Sales for Human, Humanized and Chimeric for the Years 2015, 2025 & 2030
  • TABLE 509: Africa Recent Past, Current & Future Analysis for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 510: Africa Historic Review for Antibody Therapeutics by Administration Route - Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 511: Africa 15-Year Perspective for Antibody Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 512: Africa Recent Past, Current & Future Analysis for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 513: Africa Historic Review for Antibody Therapeutics by End-Use - Hospitals, Long-term Care Facilities and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 514: Africa 15-Year Perspective for Antibody Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Long-term Care Facilities and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION